Br[C:2]1[CH:3]=[C:4]2[C:9](=[N:10][CH:11]=1)[N:8]([CH2:12][CH3:13])[CH:7]=[C:6]([C:14]([O:16][CH2:17][CH2:18][O:19][P:20]([O:30][CH2:31][C:32]1[CH:37]=[CH:36][CH:35]=[CH:34][CH:33]=1)([O:22][CH2:23][C:24]1[CH:29]=[CH:28][CH:27]=[CH:26][CH:25]=1)=[O:21])=[O:15])[C:5]2=[O:38].[CH2:39]([NH:41][C:42](=[O:62])[NH:43][C:44]1[N:49]=[CH:48][C:47](B(O)O)=[C:46]([C:53]2[S:54][CH:55]=[C:56]([C:58]([F:61])([F:60])[F:59])[N:57]=2)[CH:45]=1)[CH3:40].C(=O)([O-])[O-].[Na+].[Na+]>CN(C)C=O.[Pd].C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1>[CH2:12]([N:8]1[C:9]2[C:4](=[CH:3][C:2]([C:47]3[CH:48]=[N:49][C:44]([NH:43][C:42](=[O:62])[NH:41][CH2:39][CH3:40])=[CH:45][C:46]=3[C:53]3[S:54][CH:55]=[C:56]([C:58]([F:61])([F:59])[F:60])[N:57]=3)=[CH:11][N:10]=2)[C:5](=[O:38])[C:6]([C:14]([O:16][CH2:17][CH2:18][O:19][P:20]([O:30][CH2:31][C:32]2[CH:37]=[CH:36][CH:35]=[CH:34][CH:33]=2)([O:22][CH2:23][C:24]2[CH:25]=[CH:26][CH:27]=[CH:28][CH:29]=2)=[O:21])=[O:15])=[CH:7]1)[CH3:13]2-{[Bis(benzyloxy)phosphoryl]oxy}ethyl 6-bromo-1-ethyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate (Intermediate 25, 80 mg, 0.133 mmol) was dissolved in dimethylformamide (15 mL), and the solution was purged with argon. Tetrakis (triphenylphosphine) palladium (15 mg, 0.013 mmol) and 6-(3-ethylureido)-4-(4-(trifluoromethyl)thiazol-2-yl)pyridin-3-ylboronic acid (Intermediate 9, 71 mg, 0.16 mmol) were added and the mixture was stirred for 20 min at room temperature. Sodium carbonate solution (57 mg, 0.53 mmol) (dissolved in minimum amount of water) was added, and the reaction mixture was heated to 90° C. for 3 h. The reaction mixture was passed through celite and the celite was washed with dimethylformamide. The dimethylformamide layer was poured into water (100 mL) and a precipitate formed. The solid was filtered and dried then purified by flash column chromatography over silica gel (0-8% MeOH/CHCl3) to afford 70 mg (63%) of 2-{[bis(benzyloxy)phosphoryl]oxy}ethyl 1-ethyl-6-{6-[(ethylcarbamoyl)amino]-4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]pyridin-3-yl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate as white solid.